title: [Off-label use and G-BA. Legal framework for off-label use].
abstract: Off-label use of medicinal products, i.e. beyond their submitted, tested and approved indications, lies between 30 and 90%--depending on the indication. In dermatology, off-label use is of special importance, for even guideline-endorsed standard therapeutic approaches for common dermatological diseases like atopic eczema, psoriasis, or malignant melanoma are to some extent not licensed for these indications. In addition, many of the approximately 5000 dermatological diseases have a low prevalence. For many such orphan diseases, there are no approved drugs, and it is not feasible that licensing studies will be performed for these indications within a foreseeable time. A reliable legal framework for the reimbursement of medicinal products that are used off-label is essential both for patients and to allow physicians to choose the most adequate therapy. Therefore, off-label use expert groups have been convened by the Federal Ministry of Health (BMG) in order to improve patient care. So far this new and innovative approach has not provided any reasonable improvement for many patients with dermatological diseases whose treatment can only be off-label since a comprehensive evaluation of all off-label indications is not possible. The following statement of the former Federal Minister of Health, U. Schmidt, is particularly true for dermatological therapy: "Good oncologic care also requires a good drug treatment--especially in the outpatient setting. The use of drugs which are not or not yet approved for this indication is often required here". Federal Minister of Health, Ulla Schmidt, 25th German Cancer Congress, 10 March 2002, Berlin.
authors.affiliation: VOELKER & Partner, Rechtsanwälte, Wirtschaftsprüfer, Steuerberater, Reutlingen, Deutschland.
authors.forename: U
authors.initials: U
authors.lastname: Brucklacher
authors.forename: N H
authors.initials: NH
authors.lastname: Brockmeyer
authors.forename: C
authors.initials: C
authors.lastname: Riedel
mesh_terms: D003879:Dermatologic Agents / Q000592:standards / Q000627:therapeutic use*; D003880:Dermatology / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D005858:Germany; D033161:Government Regulation; D006801:Humans; D007880:Legislation, Drug; D009313:National Health Programs / Q000331:legislation & jurisprudence*; D056687:Off-Label Use / Q000331:legislation & jurisprudence*; D010818:Practice Patterns, Physicians' / Q000331:legislation & jurisprudence*; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D003879:Dermatologic Agents